Read the full paper: Targeting c-Myc-p300-CARM1 complex induces ferroptosis and reduces CD8+ T cell exhaustion in esophageal squamous cell carcinoma

Read the full paper: m5C RNA methylation is dysregulated by oncogenic herpesviruses via c-Myc signaling to counteract host antiviral factors

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. Reprints and permissions...

Forskare har utvecklat en ny strategi för att stoppa ett protein som driver tumörtillväxt. Förhoppningen är att få fram nya läkemedel.

PQB-4, a fluorescent small-molecule ligand that targets c-MYC DNA G-quadruplexes (G4s), showed marked synergy with gemcitabine in resistant PANC-1 cells (CI = 0.027). In vivo, the ligand reduced tumo....

Read the full paper: Targeted O-GlcNAcylation enables functional rewiring of c-Myc

Read the full paper: SDCBP competes with CBL to stabilize PES1 and promote c-Myc translation in ESCC tumorigenesis

Xu et al. introduce OGTAC, a chemically induced proximity strategy that recruits O-GlcNAc transferase to c-Myc to achieve targeted post-translational modification (PTM) rather than degradation. The study establishes PTM editing as an approach for rewiring transcription factor activity.

Chinese medical journal · Liu C, Wang W, Wang F, Xing H, Cao W, Jiang Z.

Here, we identify METTL15, an N4-methylcytidine (m4C) RNA methyltransferase, as a novel oncogenic driver of this metabolic reprogramming.

Read the full paper: NAT10 promotes prostate cancer progression by acetylating mRNA of MARK2 and activating mTOR/HIF-1α/C-Myc pathway to enhance glycolytic reprogramming

Researchers at Umeå University have developed a strategy to slow the growth of tumor cells. By targeting the genetic instructions that control the production of a key cancer-related protein, they were able to inhibit tumor cell growth.

The C-Myc Antibody Market is expected to grow from 1,100 USD Million in 2025 to 2,500 USD Million by 2035. The C-Myc Antibody Market CAGR (growth rate) is expected to be around 8.3% | Wiseguy Reports